File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)

TitleNovel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)
Authors
KeywordsDuctal carcinoma in situ
Neoadjuvant systemic therapy
Trastuzumab (Herceptin)
Issue Date2007
PublisherBlackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journals/TBJ
Citation
Breast Journal, 2007, v. 13 n. 1, p. 72-75 How to Cite?
AbstractBecause ductal carcinoma in situ (DCIS) avidly expresses Her2/neu, the target of the monoclonal antibody trastuzumab, and because trastuzumab has been shown to be effective against invasive breast cancer, trastuzumab may be effective for reducing the tumor burden and abrogating or reversing the hypothesized transition from in situ to invasive disease in patients with DCIS. To test this hypothesis, a trial of neoadjuvant trastuzumab for DCIS has been opened at our institution. Because trastuzumab has been shown to act as a radiosensitizing agent for Her2/neu-overexpressing cancer and because there are currently no systemic treatments for estrogen-receptor-negative DCIS, it makes sense to investigate whether use of trastuzumab concurrently with postoperative radiation therapy improves local control of DCIS. The National Surgical Adjuvant Breast and Bowel Project (NSABP) is planning a trial to test this hypothesis. The risk of cardiac toxicity associated with the doses of trastuzumab planned for these trials (cumulative doses of 8 mg/kg for our trial and 14 mg/kg in the NSABP trial) is believed to be minimal, but the safety profile of these approaches will need to be closely monitored. © 2007, Copyright the Authors.
Persistent Identifierhttp://hdl.handle.net/10722/146579
ISSN
2015 Impact Factor: 1.92
2015 SCImago Journal Rankings: 0.803
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorGonzalez, RJen_HK
dc.contributor.authorBuzdar, AUen_HK
dc.contributor.authorFraser Symmans, Wen_HK
dc.contributor.authorYen, TWen_HK
dc.contributor.authorBroglio, KRen_HK
dc.contributor.authorLucci, Aen_HK
dc.contributor.authorEsteva, FJen_HK
dc.contributor.authorYin, Gen_HK
dc.contributor.authorKuerer, HMen_HK
dc.date.accessioned2012-05-02T08:37:10Z-
dc.date.available2012-05-02T08:37:10Z-
dc.date.issued2007en_HK
dc.identifier.citationBreast Journal, 2007, v. 13 n. 1, p. 72-75en_HK
dc.identifier.issn1075-122Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/146579-
dc.description.abstractBecause ductal carcinoma in situ (DCIS) avidly expresses Her2/neu, the target of the monoclonal antibody trastuzumab, and because trastuzumab has been shown to be effective against invasive breast cancer, trastuzumab may be effective for reducing the tumor burden and abrogating or reversing the hypothesized transition from in situ to invasive disease in patients with DCIS. To test this hypothesis, a trial of neoadjuvant trastuzumab for DCIS has been opened at our institution. Because trastuzumab has been shown to act as a radiosensitizing agent for Her2/neu-overexpressing cancer and because there are currently no systemic treatments for estrogen-receptor-negative DCIS, it makes sense to investigate whether use of trastuzumab concurrently with postoperative radiation therapy improves local control of DCIS. The National Surgical Adjuvant Breast and Bowel Project (NSABP) is planning a trial to test this hypothesis. The risk of cardiac toxicity associated with the doses of trastuzumab planned for these trials (cumulative doses of 8 mg/kg for our trial and 14 mg/kg in the NSABP trial) is believed to be minimal, but the safety profile of these approaches will need to be closely monitored. © 2007, Copyright the Authors.en_HK
dc.languageengen_US
dc.publisherBlackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journals/TBJen_HK
dc.relation.ispartofBreast Journalen_HK
dc.subjectDuctal carcinoma in situen_HK
dc.subjectNeoadjuvant systemic therapyen_HK
dc.subjectTrastuzumab (Herceptin)en_HK
dc.subject.meshAntibodies, Monoclonal - Therapeutic Useen_US
dc.subject.meshAntibodies, Monoclonal, Humanizeden_US
dc.subject.meshAntineoplastic Agents - Therapeutic Useen_US
dc.subject.meshBreast Neoplasms - Drug Therapy - Pathologyen_US
dc.subject.meshCarcinoma, Intraductal, Noninfiltrating - Drug Therapy - Pathologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshNeoadjuvant Therapyen_US
dc.subject.meshRandomized Controlled Trials As Topicen_US
dc.subject.meshReceptor, Erbb-2en_US
dc.subject.meshResearch Designen_US
dc.titleNovel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin)en_HK
dc.typeArticleen_HK
dc.identifier.emailYin, G: gyin@hku.hken_HK
dc.identifier.authorityYin, G=rp00831en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1524-4741.2006.00366.xen_HK
dc.identifier.pmid17214797-
dc.identifier.scopuseid_2-s2.0-33845974062en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33845974062&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue1en_HK
dc.identifier.spage72en_HK
dc.identifier.epage75en_HK
dc.identifier.isiWOS:000243732100012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridGonzalez, RJ=36094091300en_HK
dc.identifier.scopusauthoridBuzdar, AU=35379841900en_HK
dc.identifier.scopusauthoridFraser Symmans, W=7003919463en_HK
dc.identifier.scopusauthoridYen, TW=7202232668en_HK
dc.identifier.scopusauthoridBroglio, KR=6602915196en_HK
dc.identifier.scopusauthoridLucci, A=7003788043en_HK
dc.identifier.scopusauthoridEsteva, FJ=7006408804en_HK
dc.identifier.scopusauthoridYin, G=8725807500en_HK
dc.identifier.scopusauthoridKuerer, HM=7006194871en_HK
dc.identifier.citeulike1027358-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats